The IMI PROTECT project: purpose, organizational structure, and procedures


Research output: Contribution to journalArticleAcademicpeer-review


The Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium (PROTECT) initiative was a collaborative European project that sought to address limitations of current methods in the field of pharmacoepidemiology and pharmacovigilance. Initiated in 2009 and ending in 2015, PROTECT was part of the Innovative Medicines Initiative, a joint undertaking by the European Union and pharmaceutical industry. Thirty-five partners including academics, regulators, small and medium enterprises, and European Federation of Pharmaceuticals Industries and Associations companies contributed to PROTECT. Two work packages within PROTECT implemented research examining the extent to which differences in the study design, methodology, and choice of data source can contribute to producing discrepant results from observational studies on drug safety. To evaluate the effect of these differences, the project applied different designs and analytic methodology for six drug-adverse event pairs across several electronic healthcare databases and registries. This papers introduces the organizational structure and procedures of PROTECT, including how drug-adverse event and data sources were selected, study design and analyses documents were developed, and results managed centrally.
Original languageEnglish
Pages (from-to)5-10
JournalPharmacoepidemiology and Drug Safety
Issue numberSuppl. 1
Publication statusPublished - Mar 2016


  • pharmacoepidemiology
  • Innovative Medicines Initiative
  • observational studies
  • methodology
  • electronic healthcare databases
  • European Medicines Agency

Cite this